← Back to patent-cliff list
Oxandrolone subdermal (Stin Pharma)
Tier C — Watch / tradeOxandrolone subdermal (Stin Pharma)
Stin Pharma Excelencia em Saude Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AR
Indications (approved)：前交叉韧带损伤
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Oxandrolone subdermal (Stin Pharma)?
Approved indications include: 前交叉韧带损伤.
When does the Oxandrolone subdermal (Stin Pharma) patent expire?
No public expiry year is available for Oxandrolone subdermal (Stin Pharma) yet; this page updates once verified.
How do I get a quote for Oxandrolone subdermal (Stin Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30